Skip to main content

Complera FDA Approval History

FDA Approved: Yes (First approved August 10, 2011)
Brand name: Complera
Generic name: emtricitabine, rilpivirine and tenofovir disoproxil fumarate
Dosage form: Tablets
Company: Gilead Sciences, Inc.
Treatment for: HIV Infection

Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is a combination of three antiretroviral medications indicated for the once daily treatment of HIV-1 infection in treatment-naïve adults.

Development timeline for Complera

Aug 10, 2011Approval U.S. Food and Drug Administration Approves Gilead Sciences' Complera, a New Complete Once-Daily, Single-Tablet Regimen for HIV-1 Infection in Treatment-Naïve Adults

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.